Clinical trial · Observational
Does Acne Rash During Adolescence Predict Skin Reaction to Cetuximab
Does Acne Rash During Adolescence Predict Skin Reaction to Cetuximab?
NCT01382407CI-TRIAL-00027231completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The hypothesis of this study is that patients who suffered from acne vulgaris during adolescence are at greater risk of developing acneiform skin rash due to cetuximab.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer Metastatic | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cetuximab | Drug | Cetuximab | ALIAS |
Design
Arms and outcomes
Arms (1)
- label
- Cetuximab
- description
- All patients who started treatment with ERBITUX® (cetuximab), as a single agent or in combination with chemotherapy.
- interventionNames
- Drug: Cetuximab
Primary outcomes (1)
- measure
- Relationship between acne and skin rash
- timeFrame
- Within Erbitux treatment period (upto 12 months)
- description
- To determine whether there is a relationship between acne during adolescence and skin rash during cetuximab treatment?
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age above 18 years. * Histology or cytology proven KRAS-WT mCRC. * Performance status ≤3 (Eastern Cooperative Oncology Group \[ECOG\] classification) * Life expectancy of more than 12 weeks. * Written informed consent. * In women of childbearing potential, appropriate contraceptive measures must be used during treatment with cetuximab and for 6 months following the last dose of cetuximab. Exclusion Criteria: * Past systemic immune therapy for disease other than cancer. * Past immune or other target therapy for cancer (not including bevacizumab). * Presence of acne or acneiform rash prior to starting treatment with cetuximab. * Patients with treatment plan of cetuximab and capecitabine combination. * For female patients: the patient is pregnant or lactating.
References
Publications (0)
Data not yet available
No reference posted for this study.